posaconazole - Profile

What are the generic sources for posaconazole and what is the scope of freedom to operate?

Posaconazole is the generic ingredient in three branded drugs marketed by Msd Merck Co, Merck Sharp Dohme, Aspiro, Eugia Pharma, Fresenius Kabi Usa, Gland, Mylan Labs Ltd, Ph Health, Schering, Hikma, Actavis Labs Fl Inc, Aet Pharma, Amneal, Aurobindo Pharma, Biocon Pharma, Dr Reddys, Hetero Labs Ltd Iii, I 3 Pharms, MSN, Qilu Pharm Hainan, Sinotherapeutics Inc, Specgx Llc, and Welding, and is included in twenty-four NDAs. There are six patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Posaconazole has eighty-one patent family members in twenty-four countries.

There is one tentative approval for this compound.

Summary for posaconazole

International Patents:	81
US Patents:	6
Tradenames:	3
Applicants:	23
NDAs:	24
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for posaconazole

Generic filers with tentative approvals for POSACONAZOLE

Applicant	Application No.	Strength	Dosage Form
		18MG	INJECTION;SOLUTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for POSACONAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NOXAFIL	Injection	posaconazole	18 mg/mL, 16.7 mL vials	205596	1	2015-11-24
NOXAFIL	Delayed-release Tablets	posaconazole	100 mg	205053	1	2014-06-16
NOXAFIL	Oral Suspension	posaconazole	40 mg/mL	022003	1	2011-02-28

US Patents and Regulatory Information for posaconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	NOXAFIL POWDERMIX KIT	posaconazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	214770-001	May 31, 2021		RX	Yes	Yes
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	9,023,790		Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	9,358,297		Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	9,750,822		Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	9,493,582		Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	10,117,951		Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	8,410,077		Y

Expired US Patents for posaconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	6,958,337
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	8,263,600
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014	5,661,151
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	5,703,079
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	5,661,151
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014	5,703,079
Merck Sharp Dohme	NOXAFIL	posaconazole	TABLET, DELAYED RELEASE;ORAL	205053-001	Nov 25, 2013	5,703,079

EU/EMA Drug Approvals for posaconazole

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Noxafil	posaconazole	EMEA/H/C/000610Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.	Authorised	no	no	no	2005-10-25
Accord Healthcare S.L.U.	Posaconazole AHCL	posaconazole	EMEA/H/C/005028Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Accord Healthcare S.L.U.	Posaconazole Accord	posaconazole	EMEA/H/C/005005Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Schering-Plough Europe	Posaconazole SP	posaconazole	EMEA/H/C/000611Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Withdrawn	no	no	no	2005-10-25

International Patents for posaconazole

Country	Patent Number	Title	Estimated Expiration
Australia	2009241858
Brazil	PI0905080
Canada	2702603
Canada	2771879
China	101959508
China	105288650
China	114053423

Supplementary Protection Certificates for posaconazole

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0736030	SPC/GB06/007	United Kingdom		PRODUCT NAME: POSACONAZOLE, OPTIONALLY IN THE FORM OF AN ESTER OR PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/05/320/001 20051025; UK EU/1/05/321/001 20051025
0736030	06C0009	France		PRODUCT NAME: POSACONAZOLE; REGISTRATION NO/DATE: EU/1/05/320/001 20051025

Assessment of Posaconazole: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Posaconazole, marketed primarily as a broad-spectrum triazole antifungal, exhibits significant commercial potential owing to the increasing prevalence of invasive fungal infections (IFIs) in immunocompromised populations. This analysis evaluates its current market landscape, future growth prospects, competitive positioning, regulatory environment, and financial trajectory to inform strategic investment decisions.

---

What Are the Current Market Dynamics for Posaconazole?

Market Overview & Key Drivers

Aspect	Details
Market Size (2022)	Estimated global antifungal market valued at $4.7 billion, projected to reach $8.2 billion by 2030 (CAGR 7.5%) [1].
Posaconazole's Role	Key player in prophylaxis and treatment of invasive Aspergillosis and mucormycosis, especially among hematology, transplant, and oncology patients. (Pfizer, 2022).
Major Indications	Oral and intravenous formulations for invasive fungal infections, with off-label use expanding due to其 efficacy.
Growth Catalysts	Rising immunosuppressed patient populations; increasing awareness of fungal infections; expanding indications including invasive candidiasis.
Competitive Landscape	Dominated by Pfizer with the market share of Norvatis’ Isavuconazole and generic formulations entering the antifungal segment.
Pricing & Reimbursement	Pricing varies geographically; higher margins in developed markets with supportive reimbursement policies (e.g., US, Europe).

Market Share & Competitive Positioning

Company	Product	Market Share (2022)	Key Features
Pfizer	Noxafil (Posaconazole)	~65%	First oral formulation; broad-spectrum antifungal
Merck (formerly)	Isavuconazole	~20%	FDA-approved for invasive aspergillosis & mucormycosis
Generics (various)	-	~15%	Lower-cost alternatives; limited patent exclusivity

---

What Is the Investment Scenario for Posaconazole?

1. Revenue Forecasts & Financial Trajectory

Year	Estimated Revenue (USD billion)	Assumptions	Source/Methodology
2023	1.2	Market penetration stabilizing, increased adoption in niches	Analyst consensus
2025	1.5	Expansion in emerging markets, new indications, increased uptake	Market penetration models
2030	2.4	Growth from unmet needs, patent expiration in some markets, generic entry	Competitive dynamics modeling

2. Investment Risks & Opportunities

Risks	Opportunities
Patent expiry and generic competition	Entry into new indications, markets, and formulations
Pricing pressures in mature markets	Increasing adoption due to rising IFI rates
Regulatory delays or restrictions	Potential for biosimilar or fixed-dose combination products
Dependence on immunocompromised demographics	Growing awareness and prophylactic use in high-risk groups

3. R&D & Pipeline Considerations

• Limited pipeline; focus remains on optimizing existing formulations and expanding approved indications.
• Potential for new formulations (e.g., inhalational delivery) under investigation, possibly extending product lifecycle.

---

How Do Market Dynamics Impact Financial Trajectory?

Regulatory Landscape & Patent Lifecycle

Aspect	Impact on Financials	Status/Notes
Patent expiration (Noxafil patents expiring 2027-2030)	Entry of generics could reduce revenue by 30-50%	Anticipated patent cliff; strategic shift needed to mitigate profit decline.
Approval of biosimilars or alternatives	Introduces pricing competition	Regulatory approval pathways in the US (FDA), EU (EMA) becoming more streamlined.
Regulatory hurdles for new indications	Limit revenue expansion potential	Additional clinical trials required, extending timeframes and increasing costs.

Pricing & Reimbursement Policies

Region	Reimbursement Status	Effect on Investment
North America (US)	Favorable in institutional settings	High margins; market stability possible
European Union	Variable; influenced by health authorities	Price controls could pressure margins
Emerging Markets	Limited reimbursement; higher unmet needs	Potential growth driven by affordability initiatives

---

What Are the Comparative Aspects with Alternatives?

Aspect	Posaconazole	Isavuconazole	Amphotericin B (Liposomal)
Spectrum	Broad, including mucormycosis	Broad, similar	Broad, limited tolerability
Administration Route	Oral, IV	Oral, IV	IV only
Side Effect Profile	Favorable; fewer hepatic issues	Similar; fewer drug interactions	Significant toxicity
Cost	Higher, justified by efficacy	Slightly less expensive	Cost-effective but toxic
Patent status	Patent expiry approaching	Patents active	Established; generic available

---

Deep Dive: Key Market Growth Factors

1. Rising Incidence of Invasive Fungal Infections

• The global burden of IFIs among hematological malignancy and transplant recipients is projected to increase at a CAGR of 8.2% [2].
• The rise of immunosuppressive treatments (post-transplant, chemotherapy) heightens demand for effective prophylaxis.

2. Expansion into New Therapeutic Areas

• Investigational trials explore posaconazole’s efficacy for onychomycosis, dermatophytosis, and COVID-19 associated fungal co-infections, broadening its potential market.

3. Regulatory Approvals & Off-Label Usage

• Expanded FDA and EMA approvals for new indications can incentivize market penetration and support revenue growth.
• Increasing off-label prescribing, particularly in emerging markets, boosts volume but challenges standardization.

---

Market Entry and Expansion Strategies

Strategy	Description	Risks
Direct Market Penetration	Strengthen presence in North America, Europe, Japan through partnerships and clinics	High competition, pricing pressures
Portfolio Diversification	Development of combination therapies, inhalational forms	R&D costs, regulatory hurdles
Licensing & Collaborations	Partner with regional players, generic manufacturers	Dependence on partner stability, IP risks
Digital & Value-Based Models	Implement subscription-based access, real-world evidence generation	Market acceptance, reimbursement challenges

---

Financial Trajectory Summarized in Table

Timeframe	Revenue Estimate	Key Drivers	Risks/Challenges
2023	$1.2 billion	Existing patent protections, established markets	Patent expiry, competition from generics
2025	$1.5 billion	Growth in emerging markets, new indications	Regulatory delays, pricing pressures
2030	$2.4 billion	Aging populations, expanded indications, pipeline evolution	Patent cliff, market saturation

---

Key Takeaways

• Market Growth: The antifungal segment, especially for invasive and prophylactic applications, presents a compound annual growth rate (CAGR) of approximately 7.5%, underpinning positive revenue forecasts for posaconazole.
• Patent Lifecycle: Patent expiry between 2027-2030 suggests imminent generic competition, necessitating strategic differentiation and pipeline innovation.
• Revenue Potential: Estimated revenues could reach USD 2.4 billion by 2030 driven by expanding indications, increased adoption, and geographic diversification.
• Competitive Positioning: Pfizer’s dominant market share faces pressure from generics and alternative antifungals; differentiation through formulation, indications, and cost management remains critical.
• Risks and Opportunities: Patent expirations, regulatory pathways, and reimbursement policies form core risk factors; conversely, unmet needs, emerging markets, and pipeline development offer growth opportunities.

---

FAQs

1. What is the primary therapeutic advantage of posaconazole over alternatives?

Posaconazole offers broad-spectrum antifungal activity with a favorable safety profile, particularly in prophylaxis settings, with fewer hepatic side effects compared to older agents like amphotericin B.

2. How does patent expiration impact the future revenue of posaconazole?

Patent expiry is projected between 2027-2030, leading to potential revenue decline of 30-50% due to generic entry, but market expansion and new indications could partly offset this decline.

3. Are there notable regulatory hurdles for expanding posaconazole's indications?

Yes, additional clinical trials and regulatory approvals are required for new indications, which can take several years and significantly impact market penetration timelines.

4. How does geographic variation affect the market prospects of posaconazole?

Developed markets like North America and Europe have supportive reimbursement policies and established clinical practices; emerging markets present growth opportunities but face affordability and regulatory challenges.

5. What strategies are pharmaceutical companies adopting to mitigate patent cliff risks?

Companies prioritize pipeline development, seek new formulations, explore combination therapies, and expand into orphan and niche indications to sustain revenues beyond patent expirations.

---

References

[1] Grand View Research, “Antifungal Drugs Market Size, Share & Trends Analysis,” 2022.
[2] World Health Organization, “Fungal Infections: An Emerging Public Health Concern,” 2021.